Press Release
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party.
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety profile to improve compliance of patients and therefore brings clinical benefits.
CMS has rooted in the central nervous system therapeutic fields for years, continuously deploying and developing global differentiated and innovative products to strengthen its competitiveness in its advantageous specialty therapeutic fields. ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with various central nervous system products including the marketed innovative drug VALTOCO (diazepam nasal spray), the original branded drug Deanxit (flupentixol and melitracen tablets) and the innovative pipeline drug Y-3 injection (a novel brain cytoprotectant that treats stroke). Leveraging its proven clinical development capability and compliant commercialization system with high efficiency, CMS will promote the approval of ZUNVEYL in China as soon as possible to bring a new drug option for the treatment of cognitive impairment in Alzheimer’s disease patients.
About ZUNVEYL
ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients.
As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. Patent in regard to use of ZUNVEYL has already been granted in China.
About Alzheimer’s disease
Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.
Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, suggesting that Alzheimer’s disease patients still have an urgent need for safer therapies.
About ALPHA
Alpha is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive impairment with mild Traumatic Brain Injury. On July 2024, Alpha received approval by the FDA of its New Drug Application (NDA) for ZUNVEYL for the treatment of mild-to-moderate Alzheimer’s disease. Alpha will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Additionally, Alpha has three pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation for the treatment of mild-to-moderate Alzheimer’s disease, ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild Traumatic Brain Injury. For more information about Alpha and its pipeline, please visit: https://www.alphacognition.com/ .
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.
Reference:
- Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832
- Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-ther…
- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.003
- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004
- Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7
- Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.
- Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-diseas…
- Research Report on the Diagnosis and Treatment of AD Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg202…
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Long-term residency initiative strengthens UAE’s position as premier destination for investors, entrepreneurs, and skilled professionals
United Kingdom, 23rd Jun 2025 – The Dubai government continues to enhance its Golden Visa program, offering expanded opportunities for international investors, entrepreneurs, and talented professionals to secure long-term residency in one of the world’s most dynamic business hubs. The strategic initiative reinforces Dubai’s commitment to attracting global talent and fostering economic diversification in line with the UAE Vision 2071.
The Golden Visa program provides successful applicants with renewable 5 or 10-year residency permits, eliminating the traditional requirement for local sponsorship and offering unprecedented flexibility for long-term planning in the emirate. This landmark initiative has already attracted thousands of high-caliber individuals from across the globe, contributing significantly to Dubai’s knowledge-based economy transformation.
“Dubai’s Golden Visa represents our unwavering commitment to building a sustainable, knowledge-driven economy,” said a senior government official. “By welcoming exceptional talent and substantial investment, we are creating an ecosystem where innovation thrives and global partnerships flourish.”
The program encompasses multiple categories designed to attract diverse talent pools. Investors who commit a minimum of AED 2 million in property or establish companies with equivalent capital qualify for the 5-year visa. The 10-year visa targets high-net-worth individuals investing AED 10 million or more, along with specialized professionals in medicine, engineering, science, and technology.
For international investors seeking to capitalize on Dubai’s Golden Visa through property investment, International Property Alerts serves as an invaluable partner in identifying prime real estate opportunities that meet visa requirements. Their comprehensive market intelligence and expert guidance help investors navigate Dubai’s dynamic property landscape efficiently.
Entrepreneurs with innovative startups approved by relevant UAE authorities can access the program, as can outstanding students and graduates from top universities worldwide. The initiative also extends to creative professionals in arts, culture, and sports who have demonstrated exceptional achievements in their respective fields.
Recent enhancements to the program include streamlined application processes, reduced documentation requirements, and expanded eligibility criteria. Families of Golden Visa holders benefit from inclusive coverage, with spouses and children under 25 eligible for the same residency status. The program also allows holders to sponsor domestic workers and provides flexibility for extended travel without affecting residency status.
Dubai’s strategic location, world-class infrastructure, and business-friendly environment have positioned the emirate as a preferred destination for global talent. The Golden Visa program complements existing initiatives including 100% foreign ownership laws, comprehensive free zone offerings, and robust intellectual property protection frameworks.
Recognizing the complexity of Dubai’s real estate market, International Property Alerts provides essential support to Golden Visa aspirants by delivering curated property opportunities, market analysis, and investment insights. Their specialized knowledge helps investors identify properties that not only qualify for visa requirements but also offer strong potential returns in Dubai’s thriving real estate sector.
The economic impact has been substantial, with Golden Visa holders contributing billions in direct investment and generating thousands of employment opportunities for UAE nationals and residents. The program supports key sectors including technology, healthcare, renewable energy, and advanced manufacturing, aligning with national economic diversification objectives.
Application processes have been digitized through smart government platforms, enabling efficient processing and transparent tracking. Dedicated service centers provide personalized support for applicants, ensuring seamless navigation through requirements and documentation procedures.
The Golden Visa initiative reflects Dubai’s long-term vision of becoming the world’s most preferred destination for living, working, and investing. By offering stability, opportunity, and world-class quality of life, Dubai continues attracting the brightest minds and most ambitious entrepreneurs from around the globe.
For investors specifically interested in property-based Golden Visa pathways, International Property Alerts stands ready to assist with comprehensive property search services, ensuring investors find the perfect Dubai property that aligns with both their visa requirements and investment objectives.
For more information about Dubai’s Golden Visa program, eligibility requirements, and application procedures, visit the official UAE government portal or contact authorized immigration consultants.
Contact Information
For Property Investment Guidance:
International Property Alerts Specializing in Dubai Golden Visa property opportunities
Email: office@internationalpropertyalerts.com | +4420 3627 0106
Media Contact
Organization: International Property Alerts
Contact Person: Philip Clarke
Website: https://internationalpropertyalerts.com/
Email: Send Email
Country:United Kingdom
Release id:29711
View source version on King Newswire:
Dubai Expands Golden Visa Program to Attract Global Talent and Investment
This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Neuroscience Fiction Red Demon Blends Science Fantasy and Romantasy in a Visceral Indie Debut
Grounded in real neuroscience, queer-normative worldbuilding, and a rare male-POV romantic subplot, this debut carves new territory in genre fiction.
United States, 23rd Jun 2025 — Indie author Sill Bihagia announces the upcoming release of Red Demon (Oria Press, August 19, 2025), a fast-paced science fantasy novel that combines high-stakes emotion, grounded science, and romantic tension in a fresh, genre-blending debut.
After surviving the massacre of his remote mining colony, Jesse sets out to kill the immortal who spared only him: the Red Demon. But Faruhar, the so-called Red Demon, isn’t what she seems. Tormented by fragmented memories and a moral code she struggles to uphold, she’s not the mastermind Jesse trains for years to defeat. As Jesse matures into a formidable fighter, he must choose between vengeance, identity, and holding on to the life he rebuilt among the ashes.
“It reads like fantasy,” Bihagia says, “but it’s grounded in science—CRISPR, neuroscience of memory, and mycological bionetworks. That’s there under the surface for the hard SFF readers, and those who are here for the emotional stakes find a villain who remembers who she loves… even if she forgets why she kills.”
Yet for all its science, Red Demon is accessible—anchored by a bisexual thrill-seeker with ADHD, cinematic fight scenes, and a spicy romantic subplot. Pre-published copies found love with both hard SFF and romantasy readers, particularly for its rare male-POV romance arc.
Red Demon is a standalone entry point to the larger Oria universe—an indie-led series of interconnected science fantasy novels exploring memory, resilience, and the consequences of survival.
Highlights
- Grounded in neuroscience, genetics, and mycology—but never alienating
- Queer-normative worldbuilding with gender-equality
- Spicy romantic subplot, morally gray characters, and emotional depth
- A rare male POV romantasy blend with genuine cross-genre appeal
- Perfect for fans of Red Rising, The Poppy War, or Gideon the Ninth
“I had the chance to work on this fast-paced science fantasy as a proofreader, and I was mesmerized by its richly realized setting and characters. I also may or may not have threatened Sill that I need more books set in this world.”
— Danai Christopoulou, Pushcart-nominated author and editor at Hugo-nominated khōréō
Advance Reader Copies are available on NetGalley through July 17, 2025.
Print copies are available upon request for editorial reviewers, booksellers, and librarians.
The book features cover design by award-nominated Maria Spada and character art by celebrated Kateryna Vitkovska, and will be released in hardcover, paperback, and ebook formats. Sprayed-edge special editions will be available at IndieReads.org at no added cost for U.S. readers.
ABOUT THE AUTHOR
Sill Bihagia is a data analyst, sword collector, and suburban chicken farmer with a background in evolutionary and behavioral neuroscience. They live in Severna Park, Maryland with their husband and two children. Sill writes speculative fiction with mature, approachable prose, emotional wreckage, and sharp wit. Red Demon is their debut novel and second published title. Their new imprint, Oria Press, champions inclusive, human-written speculative fiction with traditional-quality polish, seeking to lift up other indie writers with similar values.
RELEASE INFO
Title: Red Demon
Author: Sill Bihagia
Genre: Science Fantasy / LGBTQ+
Release Date: August 19, 2025
Formats: Ebook, Paperback, Hardcover, eBook (via KDP & IngramSpark); Sprayed-edge editions via IndieReads.org
ISBNs:
- Paperback: 978-1-968468-00-2
- Hardcover: 978-1-968468-01-9
- eBook: 978-1-968468-02-6
- Audiobook (Forthcoming 2026): Narrated by Brandon Francis and Cassandra Trieu, produced by High Gravity Productions
For media inquiry please Sill Bihagia at:
Email: contact@oriapress.com
Media Contact
Organization: Sill Bihagia
Contact Person: Sill Bihagia
Website: https://www.sillbihagia.com
Email: Send Email
Country:United States
Release id:29688
View source version on King Newswire:
Neuroscience Fiction Red Demon Blends Science Fantasy and Romantasy in a Visceral Indie Debut
This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Author Robert Yantis introduces Gentle Eagle Garden of Scriptures, a spiritually rich, Scripture-based guide designed to help readers navigate life’s hardships, deepen their faith, and discover truth through the Holy Bible. Available now on Amazon.
Seattle, WA, Washington, United States, 23rd Jun 2025 – In a world full of uncertainty and emotional distress, Robert Yantis presents a beacon of spiritual strength through his new release, Gentle Eagle Garden of Scriptures. This deeply rooted Christian non-fiction work blends powerful Biblical teachings with prayer and motivational Scripture to guide readers toward truth, transformation, and peace. The book is now available for purchase on Amazon.
Divided into four foundational sections, Gentle Eagle Garden of Scriptures begins with select passages from the Gospel of John, where Jesus introduces His mission and invites readers into a relationship with Him. The book then transitions into a principle-based study on salvation and deliverance, promoting a lifestyle grounded in personal devotion, healthy routines, and spiritual clarity. The third section compiles biblical prayers to help believers reach out to God with confidence, while the final segment offers uplifting motivational Scriptures for enduring and overcoming life’s toughest seasons.
Why This Book Matters
Many people today possess a Bible but have yet to uncover its life-changing potential. Author Robert Yantis, also known as Raverata, has seen firsthand how Scripture can guide, heal, and transform. Through Gentle Eagle Garden of Scriptures, he offers an approachable yet profound guide for those struggling, searching, or simply seeking to deepen their faith. This book serves as a conversation starter, a study aid, and a spiritual companion, encouraging intelligent reflection and fostering universal understanding, regardless of one’s background.
Robert Yantis explains, “This book is a tool. It’s a way for people to engage with God’s Word and see for themselves the truth and hope it offers.”
About the Author
Robert Yantis has been devoted to ministry since 1977. Raised in a Christian home, he holds a Bachelor of Arts in Pastoral Studies and Bible, with a minor in Biblical languages. He has planted and pastored churches in Wisconsin and South Dakota, established Christian schools, and founded The Gentle Eagle Garden of Scriptures, an outdoor attraction displaying engraved Bible verses. With over five decades of marriage and ministry alongside his wife, Robert Yantis continues to lead, teach, and inspire through Scripture and principle-based studies.
Gentle Eagle Garden of Scriptures is a carefully curated spiritual resource drawn directly from the Holy Bible. Through excerpts from the Gospel of John, principle-centered teachings on deliverance, Bible-based prayers, and motivational verses, this book equips readers with emotional and mental strength to rise above adversity. It invites reflection, encourages devotion, and leads readers toward a meaningful connection with God.
Contact Information:
Robert Yantis
South Dakota, USA
raverata@gmail.com
605-423-3242
www.gentleeagle.com
Facebook
Media Contact
Organization: American Ebook Publisher
Contact Person: Peter Kim
Website: https://americanebookpublisher.com/
Email: Send Email
Contact Number: +18776513360
Address:2815 Elliott Avenue Suite 100, Seattle, WA, 98121
City: Seattle, WA
State: Washington
Country:United States
Release id:29682
The post Robert Yantis Offers a Spiritually Grounded Path Through Lifes Challenges appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dubai Expands Golden Visa Program to Attract Global Talent and Investment
Neuroscience Fiction Red Demon Blends Science Fantasy and Romantasy in a Visceral Indie Debut
Robert Yantis Offers a Spiritually Grounded Path Through Lifes Challenges
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
-
Press Release1 week ago
Marilyn Monroe returns: reincarnated icon launches luxury fashion label
-
Press Release3 days ago
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025
-
Press Release5 days ago
Current and Future Polyethylene Production Capacity by Region and Feedstock Type Ethane Naphtha Bio-based
-
Press Release1 week ago
Scarlet from Candy AI Named Top AI Companion of 2025
-
Press Release2 days ago
Esteemes Launches Redefining Confidence Through Everyday Essentials
-
Press Release1 week ago
Bloomen Introduces Convenient Flower Subscription Service in Toronto and Surrounding Areas
-
Press Release1 week ago
PAIR Miners swept 180 countries around the world, easily opening the passive income path of earning US dollars every day
-
Press Release1 week ago
WebsiteMachen Launches See-First Pay-Later Model to Accelerate Affiliate Website Deployment